IBD Biosimilar Inflectra Approved by TGA

IBD Biosimilar Inflectra Approved by TGA
Patient advocacy groups and the biotech industry are heralding the development and approval of biosimilars as a new day for the Inflammatory Bowel Disease’s (IBD) treatment. After the launching of the first Biosimilar Monoclonal Antibody in Europe in February and the presentation of promising research updates on the biosimilar Inflectra at the 2015 ECCO-IBD Conference,  Hospira is now

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *